Seoul, South Korea-based AI developer Neurophet has received clearance from the U.S. Food and Drug Administration (FDA) for an updated version of its brain MRI analysis software.
Neurophet Aqua AD Plus is an upgraded version of the existing Neurophet Aqua AD and features an added capability to automatically detect the location and number of suspected microbleed lesions in patients with Alzheimer’s disease, the company said. The software can also identify high-intensity lesion areas related to brain edema, which can help medical professionals evaluate risk factors associated with anti-amyloid antibody therapy and establish personalized treatment plans for individual patients, according to the firm.
"With this FDA clearance, we are now fully showcasing Neurophet's technological competitiveness in the Alzheimer's treatment sector to the U.S. market," said Bin Jun-gil, co-chief executive officer, in a news release.
